What is this medication?
Antiretroviral, Integrase Inhibitor (Anti-HIV) and Reverse Transcriptase Inhibitor (Anti-HIV)
DOVATO (Dolutegravir/Lamivudine) is indicated for treatment of HIV-1 Infection.
There has been an emergence of lamivudine-resistance hepatitis B virus (HBV) associated with lamivudine-containing antiretroviral regimens. Consider additional treatment for patients co-infected with HIV-1 and HBV. Closely monitor hepatic function in patients who are co-infected with HIV-1 and HBV who have discontinued lamivudine.
How does this medication work?
DOVATO (Dolutegravir/Lamivudine) is an integrase inhibitor, prevents HIV integrase by binding to the integrase active site and blocking the strand transfer step of retroviral DNA integration.
Lamivudine is a cytosine analog that inhibits HIV reverse transcription via viral DNA chain termination, in addition to inhibiting RNA- and DNA-dependent DNA polymerase activities of reverse transcriptase.
How should I take this medication?
Oral: Take one tablet (50mg/300mg) once daily.
Note: Dolutegravir/Lamivudine, Dovato is not a recommended initial regimen in patients with HIV RNA >500,000 copies/mL, hepatitis B virus (HBV) coinfection, or if antiretroviral treatment is going to be started before the results of genotypic resistance testing for reverse transcriptase or HBV testing are available (HHS [adult 2019]). In addition, there is a concern for lower treatment response in patients with CD4 count ≤200 cells/mm3.
How to Take: Take with or without food. Take 2 hours before or 6 hours after antiacids, sucralfate, iron or calcium containing supplements, or buffered medications.
What should I watch for while using this medication?
Before starting Dolutegravir and Lamivudine, Dovato make sure your physician is aware of any allergies or medications you currently take, and current medical conditions. Dolutegravir and Lamivudine, Dovato can cause hepatotoxicity, hypersensitivity reactions resulting in organ dysfunction, lactic acidosis, and immune reconstitution syndrome. Dolutegravir and Lamivudine, Dovato should not be used in patients with severe hepatic and renal impairment. All patients with HIV-1 should be tested for the presence of HBV prior to and when initiating Dolutegravir and Lamivudine, Dovato.
What if I miss a dose?
If you miss a dose of medication, try to take it as soon as possible. However, if it is almost time for your next dose, take only that scheduled dose. Do not take double or extra doses.
How should I store this medication?
Keep out of the reach of children at all times. Store at room temperature, 59 to 86° F (15 to 30° C). Protect from light. Keep the container tightly closed. Properly dispose of any unused medication after the expiration date.
What are the possible side effects of using this medication?
Headache, fatigue, dizziness, paresthesia, peripheral neuropathy, insomnia, skin rash, nausea, diarrhea, sore throat, abdominal pain, stomatitis, vomiting, neutropenia, elevated liver enzymes, infection, joint and muscle pain, cough, fever.
Note this is not a complete list of side effects for DOVATO (Dolutegravir/Lamivudine), only common ones.